Kyverna Therapeutics (KYTX) Interest Expenses (2023 - 2026)

Kyverna Therapeutics' Interest Expenses history runs 4 years deep, the most recent figure standing at $35.1 million for Q1 2026.

• Quarterly Interest Expenses rose 3547.25% year-over-year to $35.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.1 million (up 1094.25% YoY) and the FY2025 annual result came in at $43.8 million, up 1326.0% from the prior year.
• Interest Expenses was $35.1 million for Q1 2026 at Kyverna Therapeutics, up from $3.5 million in the prior quarter.
• Across five years, Interest Expenses topped out at $35.1 million in Q1 2026 and bottomed at -$1.6 million in Q4 2023.
• A 4-year average of $6.5 million and a median of $2.2 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2025 — Interest Expenses slumped 82.89% — and 2026, when it surged 3547.25%.
• Kyverna Therapeutics' Interest Expenses stood at -$1.6 million in 2023, then soared by 286.98% to $3.0 million in 2024, then climbed by 18.15% to $3.5 million in 2025, then soared by 904.95% to $35.1 million in 2026.
• Business Quant data shows KYTX's Interest Expenses at $35.1 million in Q1 2026, $3.5 million in Q4 2025, and $16.1 million in Q3 2025.